Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 147 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Zoster Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

NCT01751165
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Spring Valley, California • Wichita, Kansas • Uniontown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

NCT05966090
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
11
States / cities
Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

NCT03239873
View directory record Official record
Conditions
Varicella
Interventions
VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II®
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Months to 23 Months
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 30, 2026, 10:59 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

NCT05750017
View directory record Official record
Conditions
Herpes Zoster, Vaccine-Preventable Diseases
Interventions
Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo
Biological · Drug
Lead sponsor
Beijing Luzhu Biotechnology Co., Ltd.
Other
Eligibility
50 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Systems Biology of Zoster Vaccine

NCT04047979
View directory record Official record
Conditions
Zoster, Zoster Varicella, Shingles, Chicken Pox
Interventions
Shingrix®
Biological
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

NCT05871541
View directory record Official record
Conditions
Herpes Zoster (HZ), Shingles, Infectious Disease
Interventions
JCXH-105, Active Control (Shingrix)
Biological
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
50 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Hollywood, Florida • Tampa, Florida • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NCT04523246
View directory record Official record
Conditions
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
Biological · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years to 100 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Early Phase 1 Interventional Results available

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

NCT03771157
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
Interventions
Shingrix vaccine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 30, 2026, 10:59 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

NCT06693895
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

NCT01195636
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
XPF-002, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Jonesboro, Arkansas • Lomita, California • Westlake Village, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients

NCT00000953
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Sorivudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Martinez, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 30, 2026, 10:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

NCT00626327
View directory record Official record
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
7 Months to 1 Year
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
90
States / cities
Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

NCT02723773
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
7,539 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital

NCT01483378
View directory record Official record
Conditions
Herpes Zoster
Interventions
Choosing to receive the vaccine
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 30, 2026, 10:59 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

NCT05703607
View directory record Official record
Conditions
Shingles, Herpes Zoster Infection, Human
Interventions
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
35
States / cities
Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00068081
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 30, 2026, 10:59 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age

NCT07742644
View directory record Official record
Conditions
Measles, Mumps, Rubella, Varicella (Chickenpox), Measles-Mumps-Rubella+Chickenpox Vaccine
Interventions
MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
1,860 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
38
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Huntington Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

NCT02147587
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
36
States / cities
Jonesboro, Arkansas • Los Angeles, California • Santa Maria, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

New Topical Treatment for Continued Pain After Shingles

NCT00566904
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Epikeia coatings with aspirin, Epikeia coatings with lidocaine, Epikeia coatings alone
Drug · Other
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

NCT01767467
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine (GSK 1437173A), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Inverness, Florida • Chicago, Illinois • Elkhart, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 30, 2026, 10:59 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

NCT06855160
View directory record Official record
Conditions
Chickenpox
Interventions
Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
911 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 10:59 PM EDT